Holen Sie sich die Stockscreener-App
21.50
4.63%
-1.065
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$22.57
Offen:
$21.93
24-Stunden-Volumen:
1.85M
Relative Volume:
0.26
Marktkapitalisierung:
$11.12B
Einnahmen:
$11.32B
Nettoeinkommen (Verlust:
$-981.00M
KGV:
-11.01
EPS:
-1.9532
Netto-Cashflow:
$714.00M
1W Leistung:
-5.84%
1M Leistung:
+3.19%
6M Leistung:
+8.49%
1J Leistung:
-24.55%
1-Tages-Spanne:
$21.16
$21.93
1-Wochen-Bereich:
$21.16
$22.92
52-Wochen-Spanne:
$15.73
$29.35
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
21.52 | 11.66B | 11.32B | -981.00M | 714.00M | -1.9532 |
ISRG
Intuitive Surgical Inc
|
380.73 | 144.19B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
150.19 | 42.39B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.12 | 33.65B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
38.88 | 34.31B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
192.36 | 28.79B | 5.54B | 1.52B | 1.74B | 10.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Goldman Sachs Adjusts Price Target on Baxter International to $21 From $19, Maintains Neutral Rating - marketscreener.com
ETFs Investing in Baxter International Inc. Stocks - TradingView
Baxter stock reflects a diversified medical technology business - ad-hoc-news.de
Baxter International stock reflects a diversified medical portfolio and ongoing portfolio transforma - ad-hoc-news.de
Baxter International Inc. (BAX) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors - Business Wire
Retia Medical Adds Former Baxter Executive Christopher Benassi to Advisory Board - citybiz
Baxter International Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh - TradingView
Citi Sticks to Its Sell Rating for Baxter International (BAX) - The Globe and Mail
Baxter Beats Stable Value Fund 401(k) Plan Suit, For Good - Law360
A Look at Baxter International Inc (BAX) After 3.9% Decline -- G - GuruFocus
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter International balances portfolio focus and steady operations - ad-hoc-news.de
Baxter International focuses on core medical technologies as investors watch US healthcare demand - ad-hoc-news.de
Baxter International Again Defeats 401(k) Stable Value Fund Suit - Bloomberg Law News
Baxter International (BAX) Is Up 7.2% After Dual Russell 2500 Index AdditionsWhat's Changed - simplywall.st
Baxter International's Q2 2026 Earnings: What to Expect - Yahoo Finance
The Sigma Spectrum Infusion SystemBaxter International targets smarter IV safety - ad-hoc-news.de
Baxter International focuses on core healthcare business as investors watch its portfolio moves - ad-hoc-news.de
Why Baxter International Inc (BAX) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Is Baxter International (BAX) Fully Valued On Its Russell 2500 Index Additions? - Yahoo Finance
Will Dual Russell 2500 Inclusion and Stronger Sentiment Change Baxter International's (BAX) Narrative? - Yahoo Finance
Baxter International balances medical technology breadth with long-term investment themes - ad-hoc-news.de
Why Is Baxter (NYSE:BAX) Featured Across Major US Indices? - Kalkine Media
Baxter International focuses on core portfolio as investors weigh long-term growth prospects - ad-hoc-news.de
Evercore ISI Adjusts Price Target on Baxter International to $24 From $22 - Moomoo
Baxter International focuses on medical products as investors watch long-term strategy - ad-hoc-news.de
The Spectrum IQ Infusion System from Baxter Internationalsmart pumps push safer drug delivery - AD HOC NEWS
Baxter International focuses on medical products and patient care - AD HOC NEWS
The PrisMax SystemBaxter International extends care for chronic kidney patients - AD HOC NEWS
Baxter International Inc. Actuals & Estimates (SWB:BTL) - TradingView
How Baxter International Inc. (BAX) Affects Rotational Strategy Timing - Stock Traders Daily
Baxter International outlines its healthcare strategy as investors watch the stock - AD HOC NEWS
BAX News | BAXTER INTERNATIONAL INC (NYSE:BAX) - ChartMill
Baxter International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Baxter International stock on the company backdrop. Trading stays tied to the wider health care setu - AD HOC NEWS
Evercore ISI Group Lowers Price Target for Baxter International (BAX) to $22 | BAX Stock News - GuruFocus
Baxter International outlines its healthcare focus as investors watch the stock - AD HOC NEWS
The Exacta HD dialyzerBaxter International targets high-flux performance for US dialysis centers - AD HOC NEWS
Global Human Fibrinogen Concentrate Market Size/Share Worth USD 2.78 Billion by 2035 at a 11.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
A Look at Baxter International Inc (BAX) After 3.2% Decline -- G - GuruFocus
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
BAX Investors Have Opportunity to Lead Baxter International, Inc - The National Law Review
Baxter International consensus picture on Wall Street, shares trade steadily on NYSE - AD HOC NEWS
Is Baxter International stock underperforming the S&P 500? - MSN
Lazard Equity Franchise Portfolio's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact - Bioscience Association Manitoba
Baxter International, Inc. (BAX) LawsuitInvestors Urged to Contact Levi & Korsinsky Before December 15, 2025 - The National Law Review
Sigma Spectrum Infusion System from Baxter International Inc.smart alerts in a compact pump - ad-hoc-news.de
Baxter International Inc.(NYSE: BAX) added to Russell 2500 Index - marketscreener.com
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):